ArticleDrug and alcohol review2022
Challenges with buprenorphine inductions in the context of the fentanyl overdose crisis: A case series.
Article in Drug and alcohol review, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 2 syntheses or guidelines pooled it, 56 citations in OpenAlex.
- Pharmacological treatment strategies to manage precipitated withdrawal following the administration of buprenorphine in opioid use disorder: A systematic review.Addiction (Abingdon, England) · 2026Pooled it
- Systematic review on intentional non-medical fentanyl use among people who use drugs.Frontiers in psychiatry · 2024Pooled it
- Comparison of Extended-Release Buprenorphine Doses for Treating High-Risk Opioid Use: A Randomized Clinical Trial.JAMA network open · 2025Trial
- Rapid vs Standard Induction to Injectable Extended-Release Buprenorphine: A Randomized Clinical Trial.JAMA network open · 2025Trial
- Opioid agonist treatment outcomes among individuals with a history of nonfatal overdose: Findings from a pragmatic, pan-Canadian, randomized control trial.The American journal on addictions · 2025Trial
- Estimating the Daily Milligrams of Morphine Equivalent of Illicit Fentanyl Use in Los Angeles: Clinical and Epidemiological Implications.medRxiv : the preprint server for health sciences · 2026Article
- "You're Hoping for the Best, but Preparing for the Worst": Discussions of Starting Buprenorphine in the Context of Fentanyl Use with Clinicians and People Who Use Fentanyl.Journal of general internal medicine · 2026Article
- Buprenorphine initiation from fentanyl using low-dose intramuscular ketamine: a pilot study.Addiction science & clinical practice · 2026Article
- 'It wasn't to get high; it was just to get by': experiences of patients who use fentanyl during methadone treatment and opportunities for improving care in Vermont and New Hampshire.Harm reduction journal · 2026Article
- Barriers to Buprenorphine Initiation in Patients Using Fentanyl.JAMA network open · 2026Article
- Outpatient initiation of direct-to-inject buprenorphine.Drug and alcohol dependence · 2026Article
- Multilevel determinants of medication preferences for opioid use disorder among criminal-legal-involved populations: Insights from a scoping review.Drug and alcohol dependence reports · 2025Review
- Post-marketing Surveillance of Intranasal Nalmefene: Prevalence and Clinical Relevance of Precipitated Withdrawal.Cureus · 2025Article
- Perspectives on medication for opioid use disorder (MOUD) access and service delivery among a community sample of people who use opioids in Los Angeles.Journal of substance use and addiction treatment · 2025Article
- Assessing inequities in buprenorphine treatment across the care cascade.Drug and alcohol dependence · 2025Observational
- Outpatient Low-Dose Initiation of Buprenorphine for People Using Fentanyl.JAMA network open · 2025Article
- Initiation and Dosing of Extended-Release Buprenorphine: A Narrative Review of Emerging Approaches for Patients Who Use Fentanyl.Substance abuse and rehabilitation · 2025Review
- Buprenorphine treatment and clinical outcomes under the opioid use disorder cascade of care.Drug and alcohol dependence · 2024Article
- Buprenorphine-Precipitated Withdrawal Among Hospitalized Patients Using Fentanyl.JAMA network open · 2024Article
- Methadone Initiation in the Emergency Department for Opioid Use Disorder.The western journal of emergency medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
INTRODUCTION AND
aimsNorth America is currently experiencing an epidemic of opioid overdose deaths, driven by the proliferation of fentanyl in the street drug market. Although buprenorphine/naloxone (BUP/NX) is an evidence-based, first-line opioid agonist for the management of opioid use disorder, a key challenge in its prescribing lies in the fact that it can precipitate opioid withdrawal during its initial induction process. At this time, there is minimal literature on the BUP/NX induction process in individuals who use illicit fentanyl regularly. DESIGN, METHODS AND
resultsA case series from a Vancouver, Canada addiction medicine clinic of three fentanyl-exposed patients who experienced unexpected, precipitated withdrawal when initiating BUP/NX. DISCUSSION AND
conclusionThese cases describe incidents of precipitated opioid withdrawal occurring after unusually long periods of fentanyl abstention. Although fentanyl is experienced as a short-acting opioid, the drug persists much longer in the body's peripheral tissues. Here, we highlight the new challenges fentanyl may pose to current BUP/NX induction strategies, and explore the possibility of a long-acting pharmacokinetic effect of fentanyl in the setting of repeated illicit use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.